Arvind Suri
General Practice · Waterbury, CTNPI 1780856252
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 201 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 46.0% of the total. 2025 is the largest year on record at $1,917, more than ten times the $30 reported in 2019. Among general practice clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $29.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- AbbVie$798
- Boehringer Ingelheim$548
- Lilly USA, LLC$330
- GSK$251
- Astellas Pharma US Inc$212
- plus $1K from 18 others
What the payments were for
- Food & beverage$5,70497%
- Education$1523%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 67 | $2,693 |
| AbbVie(2 entities) | 45 | $798 |
| Boehringer Ingelheim | 15 | $548 |
| Lilly USA, LLC | 15 | $330 |
| GSK | 3 | $251 |
| Astellas Pharma US Inc | 10 | $212 |
| Phathom Pharmaceuticals, Inc. | 3 | $167 |
| Sanofi-aventis U.S. LLC | 6 | $121 |
| Novo Nordisk | 6 | $115 |
| Exact Sciences | 5 | $114 |
| Bayer | 4 | $77 |
| Amgen | 3 | $66 |
| Eisai Inc. | 4 | $65 |
| Pfizer | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 2 | $48 |
| Medtronic(2 entities) | 2 | $43 |
| Corcept Therapeutics | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,857 in reported general payments places this provider in the 95th percentile of 1,190 general practice providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $66,169 |
| JardianceEmpagliflozin | 32 | $54,506 |
| JanuviaSitagliptin Phosphate | 30 | $50,552 |
| FarxigaDapagliflozin Propanediol | 21 | $36,093 |
| TrulicityDulaglutide | 20 | $25,188 |
| EliquisApixaban | 18 | $22,807 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $19,077 |
| XareltoRivaroxaban | 27 | $19,066 |
| MyrbetriqMirabegron | 13 | $14,065 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $10,917 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $9,670 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $8,409 |
| Repatha SureclickEvolocumab | 12 | $6,474 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $5,470 |
| SynthroidLevothyroxine Sodium | 39 | $3,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $115 | $66,16954 claims |
| MerckJanuvia, Janumet Xr | $11 | $56,02242 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,693 | $55,16943 claims |
| Boehringer IngelheimJardiance | $548 | $54,50632 claims |
| Lilly USA, LLCTrulicity | $330 | $25,18820 claims |
| PfizerEliquis | $53 | $22,80718 claims |
| Astellas Pharma US IncMyrbetriq | $212 | $14,06513 claims |
| GSKBreo Ellipta | $251 | $10,91727 claims |
| AbbVieSynthroid | $798 | $3,60639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,190 general practice providers in Connecticut.
Other general practice in Waterbury
- Vincent RaucciNorth Haven$268K
- Jeffrey HoosStratford$113K
- James CrossHartford$73K
- David FantarellaNorth Haven$33K
- David EdelsonPlainville$29K
- Yousong WangNew Britain$23K
- Michael YoungWindsor$16K
- Julia LathamStratford$13K
- Lawrence ChristianSimsbury$12K
- Alexander QuintnerMilford$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.